药物对比
Tirzepatide vs Insulin Degludec
比较Tirzepatide（Mounjaro）与Insulin Degludec（Tresiba）治疗2型糖尿病。双重受体激动剂与基础胰岛素：疗效、体重、风险、警告。
此页面暂无可用的对比维度。
临床背景
Type 2 diabetes patients requiring injectable therapy compare dual incretin agonist tirzepatide against long-acting insulin degludec for optimal control and weight management.
结论
Tirzepatide typically outperforms basal insulin in weight and A1C for T2D but cannot replace insulin in all cases.
全部药物对比